The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Individual differences in clinical responsiveness to antiepileptic drugs are due to a complex interaction between environmental factors and genetic variation. Considerable interest has arisen in exploiting advances in molecular genetics to improve drug therapy for epilepsy and many other diseases; however, practical application of pharmacogenetics has been difficult to realize. Attempts to define gene variants that are associated with therapeutic (or adverse) effects of antiepileptic drugs rely currently on the prior identification of candidate genes and the subsequent evaluation of the distribution of allelic variants between individuals who have a "good" versus a "poor" clinical response. Many factors can adversely affect interpretation of such data, and careful consideration must be given to the design of genetic association studies involving candidate genes. Candidate genes may be identified in a number of ways; however, for studies of drugs, application of knowledge derived from basic pharmacology can suggest focused and testable hypotheses that are based on the fundamental principles of drug action. Thus, studies of genetic variation as they relate to proteins involved in antiepileptic drug kinetics and dynamics will identify key polymorphisms in endogenous molecules that determine degrees of drug efficacy and toxicity. Delineation of these effects in the coming years will promote enhanced success in the treatment of epilepsy.
Departments of Psychiatry and Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA. tnf@mail.med.upenn.edu
Thomas N
TN
Ferraro
Russell J
RJ
Buono
D000927:Anticonvulsants / Q000627:therapeutic use*; D019295:Computational Biology; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics*; D014644:Genetic Variation; D006801:Humans; D010597:Pharmacogenetics
D000927:Anticonvulsants